Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Eni SpA (E) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Eni SpA — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Eni SpA trades at $48.45 (market cap $68.81B). The key difference: Eni SpA is the larger of the two by market cap, and Eni SpA pays a 5.12% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | E | |
|---|---|---|
Market Cap | $39.89B | $68.81B |
Sector | Health | Energy |
52-Week High | $491.22 | $57.61 |
52-Week Low | $278.09 | $32.93 |
Enterprise Value | $38.15B | $87.72B |
Dividend Yield | — | 5.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
E trades at $47.72, down 0.4% on the day, with a bullish technical signal despite recent earnings volatility. The company maintains stable cash flows with $238M net cash flow in 2025 and a dividend yield of 1.3%. Recent strategic moves include lithium investments in Chile and energy trading partnerships, diversifying beyond traditional oil and gas operations. Valuation metrics appear attractive with P/E of 21.05 and P/S of 0.77, though revenue has declined from $132.5B in 2022 to $82.2B in 2025.
The outlook balances value opportunities against execution risks. Analysts show cautious optimism with 34.6% buy ratings, but declining revenue and margin pressure pose challenges. Key catalysts include successful integration of new energy ventures and oil price stability, while geopolitical tensions and energy transition costs represent significant headwinds for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →
